> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# ICU Medical Hits Its Debt Target After Repaying $80 Million, Eyes Shifting 'Value From Debt To Equity'
- URL: https://www.bullished.co/icu-medical-hits-its-debt-target-after-repaying-80-million-eyes-shifting-value-from-debt-7bf1169c/
- Published: 2026-11-06T07:57:46.000Z
- Updated: 2026-11-06T07:57:46.000Z
- Description: The infusion-products maker ended the quarter with $1.16 billion of debt and $302 million of cash, and will keep paying down debt.
- Author: Matteo Parrino
- Tags: Earnings, ICUI, Industry: Healthcare

ICU Medical, which makes infusion therapy, vascular access and vital care products, repaid [$80 million of debt](https://www.benzinga.com/news/26/11/62959435/icu-medical-q3-2026-earnings-call-transcript?ref=bullished.co) in the third quarter and has reached its leverage goal, CEO Vivek Jain said on the company's earnings call Thursday. Next comes a capital allocation review in the new year.

## Leverage target reached

Jain, who is CEO and chairman, said the company has hit its target of net leverage at two times or below, a level he called appropriate for a manufacturer growing in the mid-single digits. Debt paydown continues in the fourth quarter, and the company will weigh its capital allocation choices in the new year based on the macro factors at that time.

CFO Brian Bonnell said the quarter ended with [$1.16 billion](https://www.benzinga.com/news/26/11/62959435/icu-medical-q3-2026-earnings-call-transcript?ref=bullished.co) of debt and $302 million of cash. Free cash flow was $83 million, including $11 million of tariff refunds, along with lower restructuring and integration spending and the timing of capital spending.

Through the first nine months, free cash flow reached $173 million, already above the original full-year target of $150 million, Bonnell said. He credited $31 million of tariff refunds, lower capital spending and higher earnings, and said the fourth quarter will be weaker on higher capital spending and no material refund benefit.

## A thin share base and few acquisitions

Jain said the company has tried to protect its share base, with the only meaningful dilution coming from shares used in the Hospira and Smith transactions. He said returning capital "can be attractive on a thin share base."

External acquisition needs are minimal, he said, because the company has enough organic innovation in-house. A changing interest rate environment is the "only wildcard." His closing aim was "to be able to transfer value from debt to equity."

The company is also working to bring free cash flow back to the level management expected when it did its last transaction. Jain said the improvement this quarter came from less cash consumed by restructuring and remediation. Bonnell said remediation spending continues near term, with room to cut it further next year, which would narrow the gap between free cash flow and adjusted net income.

## Quarter and outlook

Third-quarter revenue was $556 million, up 5% organically and 4% as reported, with adjusted EPS of $2.44 and adjusted EBITDA of $114 million, according to the call. Management now expects full-year adjusted EBITDA and adjusted EPS toward the higher end of the prior ranges of $415 million to $435 million and $8.60 to $9.00.

Management said it will detail on its February call how it plans to offset 2027 cost pressures, including possible Section 232 tariffs, which Bonnell said could be harder to overcome.

The company's market value was $4.3 billion as of the original report, and the next update on 2027 cost pressures comes on the February call.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [ICU Medical (ICUI) Beats Q3 Earnings and Revenue Estimates](https://finance.yahoo.com/healthcare/articles/icu-medical-icui-beats-q3-000013372.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Icu Medical signals 2026 results toward high end of $415M-$435M EBITDA and $8.60-$9 EPS range as logistics consolidation normalizes (NASDAQ:ICUI) | Seeking Alpha](https://seekingalpha.com/news/4667615-icu-medical-signals-2026-results-toward-high-end-of-415m-435m-ebitda-and-8%5F60-9-eps-range-as?ref=bullished.co) — seekingalpha.com
- [ICU Medical (ICUI) Reports Q3 Earnings: What Key Metrics Have to Say](https://finance.yahoo.com/markets/stocks/articles/icu-medical-icui-reports-q3-233002888.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [ICU Medical: Q3 Earnings Snapshot](https://finance.yahoo.com/healthcare/articles/icu-medical-q3-earnings-snapshot-224135250.html?ref=bullished.co) — Associated Press
- [ICU Medical Q3 2026 Earnings Call Transcript](https://www.benzinga.com/news/26/11/62959435/icu-medical-q3-2026-earnings-call-transcript?ref=bullished.co) — benzinga.com